The first‐ever durable full remission (lasting more than 3 years) in solid tumours was achieved with an off‐the‐shelf CAR‐T method using CRISPR‐edited T cell therapy (CTX130) that targets CD70 in advanced renal cell carcinoma [238]. This evidence concerns the gene CD70 and hereditary clear cell renal cell carcinoma.